Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission (CSRC) to issue a maximum of 2 billion RMB in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of 650 million RMB as of the announcement date [1] Summary by Sections - **Bond Issuance Details** - The bond will be issued in tranches, with the current issuance amount not exceeding 300 million RMB (including 300 million RMB) [1] - The face value of the bond is set at 100 RMB, and the issuance price is also 100 RMB [1] - The expected start date for the offline issuance of this corporate bond is October 24, 2025 [1]

Core Viewpoint - The company, Universal Medical (02666), has received approval from the China Securities Regulatory Commission (CSRC) to issue a maximum of 2 billion RMB in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of 650 million RMB as of the announcement date [1] Group 1 - The company's wholly-owned subsidiary, China Universal Leasing Co., Ltd., is the issuer of the bonds [1] - The bonds will be issued in tranches, with the current issuance amount not exceeding 300 million RMB [1] - The face value of the bonds is set at 100 RMB, with an issuance price also at 100 RMB [1] Group 2 - The expected start date for the offline issuance of these corporate bonds is October 24, 2025 [1]

Core Viewpoint - The company, Global Medical (02666.HK), has received approval from the China Securities Regulatory Commission to publicly issue a maximum of RMB 2 billion in domestic renewable corporate bonds aimed at qualified investors, with a remaining quota of RMB 650 million as of the announcement date [1] Group 1 - The bond issuance will be conducted in tranches, with the total principal amount for this issuance not exceeding RMB 300 million [1] - The basic term of the corporate bond is set at 1 year, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the basic term and each repricing cycle [1] - The bond includes options for the issuer to renew, defer interest payments, and redeem, with a fixed interest rate for the first cycle determined through a book-building process [1] Group 2 - The interest rate for subsequent cycles will be adjusted to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] - The net proceeds from this bond issuance will be used by the issuer to supplement operational funds [1]

Core Viewpoint - Global Medical (02666.HK) has received approval from the China Securities Regulatory Commission to issue a maximum of RMB 2 billion in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1: Company Financials - The company plans to issue bonds in tranches, with the total principal amount for this issuance not exceeding RMB 850 million [1] - The basic term of the corporate bonds is set at 3 years [1] - As of August 5, 2025, Global Medical's stock closed at HKD 6.2, down 1.27%, with a trading volume of 18.6425 million shares and a turnover of HKD 115 million [1] Group 2: Market Position - Global Medical has a market capitalization of HKD 11.879 billion, ranking 5th in the medical services sector [1] - Key financial metrics compared to industry averages are as follows: - Return on Equity (ROE): 12.68% vs. industry average of -2.25% [1] - Market capitalization: HKD 11.879 billion vs. industry average of HKD 6.855 billion [1] - Revenue: HKD 13.663 billion vs. industry average of HKD 3.704 billion [1] - Net Profit Margin: 16.53% vs. industry average of -841.37% [1] - Gross Margin: 33.61% vs. industry average of 36.84% [1] - Debt Ratio: 73.42% vs. industry average of 73.74% [1]

Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission to issue a maximum of RMB 2 billion in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1: Bond Issuance Details - The bond will be issued in tranches, with the total principal amount not exceeding RMB 850 million [1] - The basic term of the bond is set at 3 years, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the basic term and each repricing cycle [1] - The bond includes options for the issuer to extend the term, defer interest payments, and redeem the bond [1] Group 2: Interest Rate Structure - The interest rate for the first cycle will be fixed and determined through a book-building process at the time of subscription, with the coupon rate being the initial benchmark rate plus the initial spread [1] - Subsequent cycles will see the coupon rate adjusted to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be used by the issuer to supplement operational funds [1]

Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission to publicly issue a maximum of RMB 2 billion in domestic renewable corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1: Bond Issuance Details - The bond will be issued in tranches, with the total principal amount not exceeding RMB 850 million [1] - The basic term of the corporate bond is set at 3 years, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the basic term and each repricing cycle [1] - The bond includes options for the issuer to extend the term, defer interest payments, and redeem the bond [1] Group 2: Interest Rate Structure - The interest rate for the first cycle will remain fixed and will be determined through a book-building process at the time of subscription [1] - The coupon rate is set as the initial benchmark rate plus an initial spread, with subsequent cycles resetting the coupon rate to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be used by the issuer to supplement operational funds [1]